Drugs for Friedreich Ataxia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 114)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Citalopram |
Approved |
Phase 4 |
|
59729-32-7, 59729-33-8 |
2771 |
Synonyms:
[<sup>3</sup>H]-citalopram
Akarin
Bonitrile
Celapram
Celexa
Celexa®|Cipramil®|LU-10171B
Celius
Ciazil
Cilift
Cipram
CIPRAMIL
Ciprapine
Citabax
Citadur
Citalec
Citalopram
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
Citol
Citopam
Citox
|
Citrol
Cytalopram
Dalsan
Elopram
Escitalopram
Escitalopram oxalate
Humorup
Lexapro
LU 10-171-B
LU-10-171-B
Nitalapram
Oropram
PAXORAN
Pramcit
Recital
Seropram
Talam
Talohexal
Temperax
Vodelax
Zentius
Zetalo
|
|
2 |
|
Bupropion |
Approved |
Phase 4 |
|
31677-93-7, 34841-39-9, 34911-55-2 |
444 |
Synonyms:
(+-)-1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
(+-)-Bupropion
Amfebutamona
Amfebutamone
AMFEBUTAMONE HCL
amfebutamone|BW-323|Wellbutrin®|Zyban®
Amfebutamonum
BUPROPION
BUPROPION HCL
Bupropion hydrochloride
Bupropion hydrochloride, (+-)-isomer
Bupropion, (+-)-isomer
BW-323
Esteve brand OF bupropion hydrochloride
FORFIVO XL
glaxo Wellcome brand 1 OF bupropion hydrochloride
|
glaxo Wellcome brand 2 OF bupropion hydrochloride
glaxo Wellcome brand 3 OF bupropion hydrochloride
GlaxoSmithKline brand 1 OF bupropion hydrochloride
GlaxoSmithKline brand 2 OF bupropion hydrochloride
NSC-315851
Quomen
Wellbatrin
Wellbutrin
WELLBUTRIN 100
WELLBUTRIN 75
WELLBUTRIN SR
WELLBUTRIN XL
Zyban
Zyban (anti-smoking)
Zyban (bupropion)
Zyntabac
|
|
3 |
|
Dopamine |
Approved |
Phase 4 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
4 |
|
Cholecalciferol |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
67-97-0, 1406-16-2 |
5280795 10883523 |
Synonyms:
(+)-Vitamin D3
(1S,3Z)-3-[(2E)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-1-CYCLOHEXANOL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENECYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-{2-[(1R,4E,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXAN-1-OL
(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3BETA,Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
(3Β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
3-BETA,Z,7E-9,10-SECOCHOLESTR-5,7,10(19)-TRIEN-3-OL
7-DEHYDROCHOLESTEROL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
ACCRETE D3
ACIFEROL D3
ACTIVATED
Activated 7-dehydrocholesterol
ADCAL-D3
ARACHITOL
AVITICOL
BIOLIFE VITAMIN D3
BIO-VITAMIN D3
CACIT D3
CALCEOS
CALCICHEW D3
CALCICHEW D3 FTE
CALCICHEW D3 ONCE DAILY
CALCI-D
Calciferol
Calciol
CALDRINK D3
CALFOVIT D3
CC
Cholecalciferol
CHOLECALCIFEROL D3
Cholecalciferols
Cholecalciferolum
COLECAL D3
Colecalciferol
Colecalciferolum
COLEKAL-D3
COLEVIT D3
CUBICOLE D3
D3 LEMON MELTS
D3-50
D3-VIGANTOL
DEKRISTOL
DELSTEROL
Delta-D
DEPARAL
DESUNIN
DEVARON
Dihydrocholesterol
DLUX 400
D-MAX
D-TRACETTEN
|
D-VIT3
EBIVIT
E-D3
EVACAL D3
FERACOL
FULTIUM DAILY D3
FULTIUM-D3
GRANUVIT D3
HUX D3
INVITA D3
ISO D3
KORA LIQUID
MICRO-DEE
NATECAL D3
NATURE'S REMEDY VITAMIN D3
NEO-D
NPHD3
NSC-375571
Oleovitamin D3
OSTEOCAPS D3
PLENACHOL
PRO D3
PRO D3 FOLIC
PRO D3 FORTE
PROVITINA
QUINTOX
RICKETON
ROYALVIT D3
STEXEROL-D3
STIVIT-D3
SUNVIT-D3 1,000
SUNVIT-D3 10,000
SUNVIT-D3 2,000
SUNVIT-D3 20,000
SUNVIT-D3 3,000
SUNVIT-D3 400
SUNVIT-D3 5,000
SUNVIT-D3 50,000
SUNVIT-D3 800
SYNERVIT-D3
THEICAL D-3
THORENS
TRIVITAN
VIDDE-3-HYDROSOL
VI-DE3
VIDEKHOL
VIGANTOL
VIGANTOLETTEN
VIGANTOLETTEN 500
VIGORSAN
VIT D3 STREULI
VITA-D3
VITAMIN D
Vitamin D 3
VITAMIN D ASSAY SYSTEM SUITABILITY
Vitamin D NOS
Vitamin D, unspecified form
Vitamin D3
Vitamin D-3
VITINC DAN-DEE-3
ZYMAD
δ-D
|
|
5 |
|
Calcitriol |
Approved, Nutraceutical |
Phase 4 |
|
32222-06-3 |
5280453 |
Synonyms:
(1a,3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
(1alpha,3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
(1R,3S,5Z)-5-{2-[(1R,3AS,4E,7AR)-1-[(2R)-6-HYDROXY-6-METHYLHEPTAN-2-YL]-7A-METHYL-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXANE-1,3-DIOL
(1S,3R,5Z,7E)-9,10-Seco-5,7,10(19)-cholestatriene-1,3,25-triol
(1S,3R,5Z,7E)-9,10-Secocholesta-5,7,10-triene-1,3,25-triol
(1Α,3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trienetriol
(5Z,7E)-(1S,3R)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
1 alpha, 25 Dihydroxy 20 epi vitamin D3
1 alpha, 25-Dihydroxy-20-epi-vitamin D3
1 alpha,25 Dihydroxycholecalciferol
1 alpha,25 Dihydroxyvitamin D3
1 alpha,25-Dihydroxycholecalciferol
1 alpha,25-Dihydroxyvitamin D3
1,25 Dihydroxy 20 epi vitamin D3
1,25 Dihydroxycholecalciferol
1,25 Dihydroxyvitamin D3
1,25(OH)2-20EPi-D3
1,25-DHCC
1,25-Dihydroxy-20-epi-vitamin D3
1,25-Dihydroxycholecalciferol
1,25-Dihydroxyvitamin D
1,25-Dihydroxyvitamin D3
1a,25(OH)2D3
1a,25-(OH)2D3
1a,25-Dihydroxycholecalciferol
1a,25-Dihydroxyvitamin D3
1a,25-Dihydroxyvitamin D3 / 1a,25-dihydroxycholecalciferol / calcitriol
1-a-25-Dihydroxyvitamin D3
1alpha,25(OH)2D3
1alpha,25-Dihydroxycholecalciferol
1alpha,25-Dihydroxyvitamin D3
1-alpha,25-Dihydroxyvitamin D3
1-alpha-25-Dihydroxyvitamin D3
1Α,25(OH)2D3
1Α,25-dihydroxycholecalciferol
1Α,25-dihydroxyvitamin D3
1Α,25-dihydroxyvitamin D3 / 1α,25-dihydroxycholecalciferol / calcitriol
1-Α-25-dihydroxyvitamin D3
20 Epi 1alpha,25 dihydroxycholecaliferol
20-Epi-1alpha,25-dihydroxycholecaliferol
25-Dihydroxycholecalciferol
5-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol
Abbott brand OF calcitriol
alpha,25-Dihydroxyvitamin D3, 1
Alphapharm brand OF calcitriol
Bocatriol
Calcijex
Calcijex®|calcitriol|Rocaltrol®
|
Calcitriol
Calcitriol abbott brand
Calcitriol alphapharm brand
Calcitriol cryopharma brand
Calcitriol galderma brand
Calcitriol gry brand
Calcitriol jenapharm brand
Calcitriol kyramed
Calcitriol kyramed brand
Calcitriol leo brand
Calcitriol medice brand
Calcitriol nefro
Calcitriol renacare brand
Calcitriol roche brand
Calcitriol-nefro
CalcitriolNefro
Calcitriolum
Cryopharma brand OF calcitriol
D3, 1 alpha,25-Dihydroxyvitamin
D3, 1,25-Dihydroxy-20-epi-vitamin
D3, 1,25-Dihydroxyvitamin
Decostriol
DIHYDROXYCHOLECALCIFEROL
DIHYDROXYVITAMIN D 3
Dihydroxyvitamin D3
Galderma brand OF calcitriol
Gry brand OF calcitriol
Hoffmann la roche brand OF calcitriol
Hoffmann-la roche brand OF calcitriol
Jenapharm brand OF calcitriol
KyraMed brand OF calcitriol
KyraMed, calcitriol
Leo brand OF calcitriol
Medice brand OF calcitriol
Osteotriol
RenaCare brand OF calcitriol
Renatriol
Ro 21-5535
RO-215535
RO-21-5535
Rocaltrol
Roche brand OF calcitriol
Silkis
Sitriol
Soltriol
Tirocal
Topitriol
Toptriol
VECTICAL
|
|
6 |
|
Dexetimide |
Withdrawn |
Phase 4 |
|
21888-98-2 |
30843 |
Synonyms:
(+)-BENZETIMIDE
(+)-benzetimide|R 16470|Tremblex®
Dexetimida
DEXETIMIDE
|
Dexetimidum
R 16470
R-16470 [AS HYDROCHLORIDE]
TREMBLEX
|
|
7 |
|
Parasympatholytics |
|
Phase 4 |
|
|
|
8 |
|
Dopamine Uptake Inhibitors |
|
Phase 4 |
|
|
|
9 |
|
Dopamine Agents |
|
Phase 4 |
|
|
|
10 |
|
Antiparkinson Agents |
|
Phase 4 |
|
|
|
11 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
12 |
|
Antidepressive Agents |
|
Phase 4 |
|
|
|
13 |
|
Serotonin Uptake Inhibitors |
|
Phase 4 |
|
|
|
14 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 4 |
|
|
|
15 |
|
Muscarinic Antagonists |
|
Phase 4 |
|
|
|
16 |
|
Cholinergic Antagonists |
|
Phase 4 |
|
|
|
17 |
|
Vitamins |
|
Phase 4 |
|
|
|
18 |
|
Trace Elements |
|
Phase 4 |
|
|
|
19 |
|
Micronutrients |
|
Phase 4 |
|
|
|
20 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
21 |
|
Hormones |
|
Phase 4 |
|
|
|
22 |
|
Calciferol |
|
Phase 4 |
|
|
|
23 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
24 |
|
Serotonin |
Investigational, Nutraceutical |
Phase 4 |
|
50-67-9 |
5202 |
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HT|serotonin
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
|
Antemovis
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
SEROTONIN
Serotonine
sérotonine
Thrombocytin
Thrombotonin
|
|
25 |
|
Calcium |
Nutraceutical |
Phase 4 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
26 |
|
Idebenone |
Approved, Investigational |
Phase 3 |
|
58186-27-9 |
3686 |
Synonyms:
2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-1,4-benzoquinone
2-(10-HYDROXYDECYL)-5,6-DIMETHOXY-3-METHYLCYCLOHEXA-2,5-DIENE-1,4-DIONE
2-(10-HYDROXYDECYL)-5,6-DIMETHOXY-3-METHYL-P-BENZOQUINONE
2,3-DIMETHOXY-5-METHYL-6-(10'-HYDROXYDECYL)-1,4-BENZOQUINONE
6-(10-HYDROXYDECYL)-2,3-DIMETHOXY-5-METHYL-1,4-BENZOQUINONE
6-(10-HYDROXYDECYL)-2,3-DIMETHOXY-5-METHYL-P-BENZOQUINONE
|
BRN 2001459
CV 2619
idebenona
IDEBENONE
idébénone
RAXONE
|
|
27 |
|
Pioglitazone |
Approved, Investigational |
Phase 3 |
|
111025-46-8 |
4829 |
Synonyms:
(+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-{4-[2-(5-ETHYLPYRIDIN-2-YL)ETHOXY]BENZYL}-1,3-THIAZOLIDINE-2,4-DIONE
Actos
Actos®|Glustin®|pioglitazone HCl|U-72107A
Actost
AD-4833
DUETACT
Glustin
Pioglitazona
Pioglitazona [INN-Spanish]
|
PIOGLITAZONE
Pioglitazone [Ban:Inn]
Pioglitazone HCL
Pioglitazone hydrochloride
Pioglitazonum
Pioglitazonum [INN-Latin]
Poglitazone hydrochloride
U-72107
U-72107A
XAB907
ZACTOS
|
|
28 |
|
Coal tar |
Approved |
Phase 3 |
|
8007-45-2 |
|
Synonyms:
|
29 |
|
Varenicline |
Approved, Investigational |
Phase 2, Phase 3 |
|
249296-44-4 |
5310966 |
Synonyms:
6,7,8,9-Tetrahydro-6,10-methano-6H-pyrazino(2,3-H)benzazepine
7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-H)(3)benzazepine
Champix
Champix®|Chantix®|compound 9a [PMID: 16171993]|CP 526555
Chantix
CP-526,555
|
CP-526555
Tartrate, varenicline
Vareniclina
VARENICLINE
Varenicline tartrate
Vareniclinum
|
|
30 |
|
Ubidecarenone |
Approved, Investigational, Nutraceutical |
Phase 3 |
|
303-98-0 |
5281915 |
Synonyms:
(all-e)-2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione
(all-e)-2,3-Dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)-2,5-cyclohexadiene-1,4-dione
2-((all-e)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
2,3-Dimethoxy-5-methyl-6-decaprenylbenzoquinone
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methyl- 2,5-cyclohexadiene-1,4-dione
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl]-5,6-dimethoxy-3-methyl-1,4-benzoquinone
4-Ethyl-5-fluoropyrimidine
Adelir
all-trans-Ubiquinone
API 31510
API-31510
Aqua Q 10l10
Aqua Q10
Bio-quinon
Bio-quinone Q10
Coenzyme Q10
Coenzyme Q-10
CO-Enzyme Q10
CoQ
CoQ 10
CoQ10
Ensorb
Kaneka Q10
|
Kudesan
Li-Q-sorb
Liquid-Q
Neuquinon
Neuquinone
NSC-140665
NSC-140865
PureSorb Q 40
Q
Q 10AA
Q 199
Q10
Q-Gel
Q-Gel 100
Q-Ter
Ubidecarenone
UBIDECARENONE FOR SYSTEM SUITABILITY
Ubiquinone
Ubiquinone 10
Ubiquinone 50
Ubiquinone Q10
UBIQUINONE-10
Unbiquinone
Unispheres Q 10
|
|
31 |
|
Antiviral Agents |
|
Phase 3 |
|
|
|
32 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
33 |
|
interferons |
|
Phase 3 |
|
|
|
34 |
|
Interferon-gamma |
|
Phase 3 |
|
|
|
35 |
|
Protective Agents |
|
Phase 3 |
|
|
|
36 |
|
Antioxidants |
|
Phase 3 |
|
|
|
37 |
|
Ubiquinone |
|
Phase 3 |
|
|
|
38 |
|
Linoleate |
|
Phase 3 |
|
|
|
39 |
|
Hypoglycemic Agents |
|
Phase 3 |
|
|
|
40 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
41 |
|
Neurotransmitter Agents |
|
Phase 2, Phase 3 |
|
|
|
42 |
|
Cholinergic Agents |
|
Phase 2, Phase 3 |
|
|
|
43 |
|
Nicotinic Agonists |
|
Phase 2, Phase 3 |
|
|
|
44 |
|
Iron |
Approved |
Phase 1, Phase 2 |
|
7439-89-6 |
29936 |
Synonyms:
Carbonyl iron
Eisen
Electrolytic iron
Fe
FE (III) ion
Fe(3+)
Fe(III)
fer
Ferric ion
Ferric iron
Ferrum
|
Ferrum metallicum
Hierro
Iron powder
Iron(3+)
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (fe(3+))
Iron, reduced
Reduced iron
|
|
45 |
|
Cianidanol |
Approved, Withdrawn |
Phase 2 |
|
154-23-4 |
9064 |
Synonyms:
(-)-Epicatechin
(+)-(2R,3S)-5,7,3',4'-Tetrahydroxyflavan-3-ol
(+)-(2R:3S)-5,7,3',4'-Tetrahydroxyflavan-3-ol
(+)-(2R:3S)-5,7,3’,4’-Tetrahydroxyflavan-3-ol
(+)-3',4',5,7-Tetrahydroxy-2,3-trans-flavan-3-ol
(+)-3’,4’,5,7-Tetrahydroxy-2,3-trans-flavan-3-ol
(+)-Catechin
(+)-Catechin hydrate
(+)-Catechol
(+)-Cianidanol
(+)-Cyanidan-3-ol
(+)-Cyanidanol
(+)-Cyanidanol-3
(+/-)-catechin
(+/-)-catechin hydrate
(2R,3S)-(+)-Catechin
(2R,3S)-Catechin
(2R-trans)-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol
3,3',4',5,7-Flavanpentol
Acid, catechinic
Acid, catechuic
Biocatechin
CATECHIN
Catechinate
|
Catechinic acid
Catechuate
Catechuic acid
Catergen
Cianidanol
Cianidanolum
Cianidol
Cyanidanol
Cyanidanol 3
Cyanidanol-3
Cyanidol
D-(+)-Catechin
D-Catechin
D-Catechol
Dexcyanidanol
Epicatechin
KB 53
KB-53
trans-(+)-3,3',4',5,7-Flavanpentol
trans-(+)-3,3’,4’,5,7-Flavanpentol
trans3,3,4,5,7 Pentahydroxyflavane
YK-85 light yellow powder 85
Zyma
|
|
46 |
|
Tocopherol |
Approved, Investigational |
Phase 2 |
|
1406-66-2 |
|
Synonyms:
Methyltocols
tocoferol
tocoferoles
|
|
|
47 |
|
Deferiprone |
Approved |
Phase 1, Phase 2 |
|
30652-11-0 |
2972 |
Synonyms:
1,2 Dimethyl 3 hydroxy 4 pyridinone
1,2 Dimethyl 3 hydroxypyrid 4 one
1,2 Dimethyl 3 hydroxypyridin 4 one
1,2-Dimethyl-3-hydroxy-4-pyridinone
1,2-Dimethyl-3-hydroxypyrid-4-one
1,2-Dimethyl-3-hydroxypyridin-4-one
3 Hydroxy 1,2 dimethyl 4 pyridinone
3-Hydroxy-1,2-dimethyl-4(1H)-pyridone
3-Hydroxy-1,2-dimethyl-4-pyridinone
APO-066
APO-66
CP20
CP-20
DEFERIPRON
DEFERIPRONA
DEFERIPRONE
DÉFÉRIPRONE
|
DEFERIPRONI
DEFERIPRONUM
DEFERYPRON
DIMETHYLHYDROXYPYRIDONE
DMOHPO
DN-18001AF
DN-180-01-AF
Ferriprox
HDMPP
HDMPP CPD
HDPP
L1
L-1
L1 Oral chelate
PL1
PL-1
|
|
48 |
|
Cathine |
Approved, Experimental, Illicit, Vet_approved, Withdrawn |
Phase 1, Phase 2 |
|
14838-15-4, 492-39-7 |
131954576 4786 26934 |
Synonyms:
(+-)-Norephedrine
(+)-Norpseudoephedrine
(+-)-Phenylpropanolamine
2-AMINO-1-PHENYLPROPAN-1-OL
Cathina
Cathine
Cathinum
D-Cathine
Dexatrim
DL-Norephedrine
DL-Phenylpropanolamine
D-Norephedrine
d-Norpseudoephedrine
d-Nor-psi-ephedrine
FENILPROPANOLAMINA
Hydriatine
Hydrochloride, phenylpropanolamine
Katine
L-NOREPHEDRINE
L-Phenyl propanolamine
|
Mucorama
Nobese
NOREPHEDRIN
Norephedrine
Obestat
PHENYLPROPANOLAMIN
Phenylpropanolamina
Phenylpropanolamine
PHÉNYLPROPANOLAMINE
Phenylpropanolamine hydrochloride
PHENYLPROPANOLAMINUM
PPA
Prestwick_388
Prolamine
Propadrine
Propagest
Pseudonorephedrine
psi-Norephedrine
Triaminic DM
Β-HYDROXYAMPHETAMINE
|
|
49 |
|
Guaifenesin |
Approved, Investigational, Vet_approved |
Phase 1, Phase 2 |
|
93-14-1 |
3516 |
Synonyms:
3-(2-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-propanediol-1,2
3-O-Methoxyphenoxypropane 1:2-diol
Actifed C
Aeronesin
a-Glyceryl guaiacol ether
a-Glyceryl guaiacolate ether
alpha-Glyceryl guaiacol ether
alpha-Glyceryl guaiacolate ether
Amonidren
Amonidrin
AMONIDRON
Aresol
Benylin-e
Breonesin
Bronchol
CVT-2534
Ether, guaiacol glyceryl
FAMEL
FRANOLYN CHESTY
GECOLATE
Glycerin ether
Glycerin guaiacolate
Glycero-guaiacol ether
Glycerol a-(2-methoxyphenyl) ether
Glycerol a-(O-methoxyphenyl)ether
Glycerol a-guaiacyl ether
Glycerol a-guiacyl ether
Glycerol a-monoguaiacol ether
Glycerol guaiacolate
Glycerol mono(2-methoxyphenyl) ether
Glycerol-a-guajakolether
Glycerol-alpha-guajakolether
Glyceryl ether, guaiacol
Glyceryl guaiacol
Glyceryl guaiacol ether
Glyceryl guaiacolate
Glyceryl guaiacolate ether
Glyceryl guaiacyl ether
Glyceryl guaicolate
Glyceryl guiacolate
Glycerylguaiacol
|
Guaiacol glycerol ether
Guaiacol glyceryl ether
Guaiacolate, glycerol
Guaiacolglicerinetere
Guaiacuran
Guaiacurane
Guaiacyl glyceryl ether
Guaiamar
Guaianesin
Guaicol glycerine ether
Guaicol glyceryl ether
Guaifenesin
GUAIFENESIN OR GUAIPHENESIN
Guaifenesina
Guaifenesine
Guaiphenesin
Guaiphenesine
Guaiphenezine
Guaiphesin
Guiatuss
HUMABID
Humibid
Hustosil
Hytuss
LIQUFRUTA
Methoxypropanediol
Methphenoxydiol
Metossipropandiolo
MUCINEX
NIROLEX FOR CHESTY COUGH DECONGESTANT
NSC-62112
O-Methoxyphenyl glyceryl ether
Organidin NR
p-Cresyl acetate
Pneumomist
Propanosedyl
Reduton
Robitussin
Scott tussin
Scott-tussin
ScottTussin
TIXYLIX CHESTY COUGH
|
|
50 |
|
Etravirine |
Approved |
Phase 2 |
|
269055-15-4 |
193962 |
Synonyms:
Etravirina
ETRAVIRINE
INTELENCE
R165335
|
|
|
Interventional clinical trials:
(show top 50)
(show all 80)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia |
Completed |
NCT01716221 |
Phase 4 |
bupropion & Citalopram;Bupropion & Placebo;Placebo & Citalopram;Placebo & Placebo |
2 |
Pilot Trial About the Effects of Calcitriol's Treatment in the Neurological Function and Frataxin's Level in Friedreich's Ataxia Patients |
Active, not recruiting |
NCT04801303 |
Phase 4 |
Calcitriol |
3 |
A Phase III Open-Label, Single Group Extension Study of the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients |
Completed |
NCT00697073 |
Phase 3 |
Idebenone |
4 |
A Randomized, Double-Blind, Controlled, Phase 2/3 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia |
Completed |
NCT04102501 |
Phase 3 |
RT001;Placebo |
5 |
Multicenter, Safety and Efficacy, Open-Label Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia |
Completed |
NCT02593773 |
Phase 3 |
Interferon γ-1b |
6 |
Effect of Pioglitazone Administered to Patients With Friedreich's ATAXIA:Proof of Concept |
Completed |
NCT00811681 |
Phase 3 |
pioglitazone;Placebo |
7 |
Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia |
Completed |
NCT02797080 |
Phase 3 |
interferon γ-1b |
8 |
A Phase III Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients |
Completed |
NCT00537680 |
Phase 3 |
Idebenone;Placebo |
9 |
A Phase III Double-blind, Randomised, Placebo-controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients |
Completed |
NCT00905268 |
Phase 3 |
idebenone;Placebo |
10 |
Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Pharmacokinetic Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia |
Completed |
NCT02415127 |
Phase 3 |
Interferon γ-1b;Placebo |
11 |
A Phase III Open-Label, Single-Group, Extension Study to Obtain Long-Term Safety and Tolerability Data of Idebenone in the Treatment of Friedreich's Ataxia Patients. |
Completed |
NCT00993967 |
Phase 3 |
idebenone |
12 |
A Phase IIIb Double-Blind, Randomised, Placebo-Controlled Study of Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone |
Completed |
NCT01303406 |
Phase 3 |
Idebenone;Placebo |
13 |
A Randomized, Parallel-Arm, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Friedreich Ataxia (MOVE-FA) |
Active, not recruiting |
NCT04577352 |
Phase 2, Phase 3 |
Vatiquinone;Placebo |
14 |
Long-Term Open-Label Study to Assess the Safety and Efficacy of Vatiquinone in Patients With Friedreich Ataxia |
Not yet recruiting |
NCT05515536 |
Phase 3 |
Vatiquinone |
15 |
Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia |
Terminated |
NCT00803868 |
Phase 2, Phase 3 |
varenicline;placebo |
16 |
Pharmacodynamic Studies of a Histone Deacetylase Inhibitor in Friedreich's Ataxia |
Unknown status |
NCT01589809 |
Phase 2 |
nicotinamide |
17 |
Safety and Efficacy of γIFN Treatment in Friedreich Ataxia |
Completed |
NCT03888664 |
Phase 2 |
gamma interferon |
18 |
Efficacy of EGb761 120mg Bid Versus Placebo in Patients Suffering From Friedreich Ataxia. A 3 Month, Phase II, Randomised, Double Blind, Placebo Controlled, Parallel Group Clinical Study. |
Completed |
NCT00824512 |
Phase 2 |
EGb 761 120 mg;Placebo |
19 |
Open-label Pilot Study of Interferon Gamma-1b (Actimmune™) for the Treatment of Friedreich Ataxia (FRDA) |
Completed |
NCT01965327 |
Phase 2 |
Interferon Gamma-1b |
20 |
Effect of Iron-Chelating Therapy in Friedreich Ataxia. Study Phase I/II |
Completed |
NCT00224640 |
Phase 1, Phase 2 |
Iron chelating intervention |
21 |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adult Subjects With Friedreich Ataxia |
Completed |
NCT03214588 |
Phase 2 |
TAK-831;TAK-831 Placebo |
22 |
A Double-blind, Randomized, Placebo-controlled, Clinical Trial to Test the Efficacy of Epoetin Alfa on Physical Performance of Friedreich Ataxia Patients. |
Completed |
NCT01493973 |
Phase 2 |
Epoetin alfa;Placebo |
23 |
An Open Label Clinical Pilot Study of Resveratrol as Treatment for Friedreich Ataxia |
Completed |
NCT01339884 |
Phase 1, Phase 2 |
Resveratrol |
24 |
A Double-Blind, Placebo-controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological, and Clinical Markers in Patients With Friedreich's Ataxia |
Completed |
NCT03917225 |
Phase 2 |
MIN-102;Placebo |
25 |
A Phase IIa Clinical Trial to Test the Safety and Efficacy of Interferon Gamma Treatment in Elevating Frataxin Levels in Friedreich's Ataxia (FRDA) Patients |
Completed |
NCT02035020 |
Phase 2 |
gamma interferon |
26 |
A Six Month Double-Blind, Placebo-Controlled Phase 2 Clinical Trial to Determine the Safety and Efficacy of Idebenone Administered to Patients With Friedreich's Ataxia |
Completed |
NCT00229632 |
Phase 2 |
Idebenone |
27 |
A Phase II, Open Label Prospective Single Center Drug Study Evaluating the Safety and Efficacy of (+)-Epicatechin in Subjects With Friedreich's Ataxia |
Completed |
NCT02660112 |
Phase 2 |
(+)-Epicatechin |
28 |
Single-Center, Open-Label, Sequential Trial to Test the Efficacy, Safety and Tolerability of Epoetin Alfa in Patients With Friedreich's Ataxia |
Completed |
NCT00631202 |
Phase 2 |
Epoetin alfa |
29 |
A Phase 2A Clinical Trial of EPI-743 (Vincerinone™) on Visual Function in Friedreich's Ataxia Patients With Point Mutations |
Completed |
NCT01962363 |
Phase 2 |
EPI-743 |
30 |
A Six-month Double-blind, Randomized, Placebo-controlled Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia |
Completed |
NCT00530127 |
Phase 1, Phase 2 |
placebo;deferiprone |
31 |
A Randomized, Double-blind, Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of RT001 in Patients With Friedreich's Ataxia |
Completed |
NCT02445794 |
Phase 1, Phase 2 |
Low dose cohort;High dose cohort |
32 |
Randomised, Double Blind, Placebo Controlled Study of Lu AA24493 in Patients With Friedreich's Ataxia to Evaluate Safety and Tolerability and to Explore Efficacy |
Completed |
NCT01016366 |
Phase 2 |
Lu AA24493;Placebo |
33 |
An Open-label, Single Treatment, Safety and Efficacy, Long-term Study of Deferiprone in Subjects With Friedreich's Ataxia |
Completed |
NCT00897221 |
Phase 2 |
Deferiprone oral solution 100mg/mL;Deferiprone oral solution 100 mg/mL |
34 |
A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, 28 Day, Three-arm, Parallel Group Study of A0001 in the Treatment of Subjects With Friedreich's Ataxia |
Completed |
NCT01035671 |
Phase 2 |
alpha-tocopherolquinone (A0001);placebo |
35 |
Safety and Efficacy Study of EPI-743 on Visual Function in Patients With Friedreich's Ataxia |
Completed |
NCT01728064 |
Phase 2 |
Placebo;EPI-743 400 mg;EPI-743 200 mg |
36 |
An Open-Label Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Vatiquinone in Children With Friedreich Ataxia Younger Than 7 Years of Age |
Recruiting |
NCT05485987 |
Phase 2 |
Vatiquinone |
37 |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Exploration Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 in Adult Subjects With Friedreich's Ataxia |
Recruiting |
NCT05579691 |
Phase 2 |
|
38 |
A Phase 1/2 Study of the Safety and Efficacy of LX2006 Gene Therapy in Participants With Cardiomyopathy Associated With Friedreich's Ataxia |
Recruiting |
NCT05445323 |
Phase 1, Phase 2 |
|
39 |
A Phase 2 Clinical Trial to Test the Safety and Efficacy of Etravirine in Friedreich Ataxia Patients |
Active, not recruiting |
NCT04273165 |
Phase 2 |
Etravirine Tablets |
40 |
A Pilot Investigator Initiated Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide in the Treatment of Advanced Symptoms of Friedreich Ataxia (FRDA) |
Active, not recruiting |
NCT05168774 |
Phase 1, Phase 2 |
Elamipretide |
41 |
A Randomised Placebo-controlled Crossover Trial of Micronised Resveratrol as a Treatment for Friedreich Ataxia |
Active, not recruiting |
NCT03933163 |
Phase 2 |
Resveratrol |
42 |
A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe) |
Active, not recruiting |
NCT02255435 |
Phase 2 |
Omaveloxolone Capsules, 2.5 mg;Omaveloxolone Capsules, 5 mg;Omaveloxolone Capsules, 10 mg;Placebo;Omaveloxolone Capsules, 20 mg;Omaveloxolone Capsules, 40 mg;Omaveloxolone Capsules, 80 mg;Omaveloxolone Capsules, 160 mg;Omaveloxolone Capsules, 300 mg;Omaveloxolone Capsules, 150 mg |
43 |
A Phase 2a Study of NAD+ Precursor Supplementation in Friedreich's Ataxia |
Active, not recruiting |
NCT04817111 |
Phase 2 |
MIB-626 |
44 |
Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA) Phase I-II Efficacy-Toxicity of Artesunate in Friedreich Ataxia |
Not yet recruiting |
NCT04921930 |
Phase 1, Phase 2 |
Artesunate Oral Product |
45 |
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia |
Not yet recruiting |
NCT03761511 |
Phase 2 |
Nicotinamide;Placebo |
46 |
A Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia |
Completed |
NCT04176991 |
Phase 1 |
|
47 |
Phase I Clinical Trial to Establish the Maximum Tolerated Dose of Idebenone in Children, Adolescents, and Adults With Friedreich's Ataxia |
Completed |
NCT00015808 |
Phase 1 |
Idebenone |
48 |
Phase 1B Clinical Trial to Establish the Safety and Tolerability of a Multiple-Dose Regimen of Idebenone Administered to Patients With Friedreich's Ataxia |
Completed |
NCT00078481 |
Phase 1 |
Idebenone |
49 |
A Phase 1 Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia |
Completed |
NCT04519567 |
Phase 1 |
|
50 |
A Phase 1, Randomized, Double-blind, Placebo-controlled, Multicenter, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral VP 20629 in Adult Subjects With Friedreich's Ataxia |
Completed |
NCT01898884 |
Phase 1 |
VP 20629;Placebo |
|